| type 2 diabetes | 108 | 21 | $4,658M | 6 | 11 (9) | Endocrinology |
| plaque psoriasis | 95 | 37 | $2,973M | | 17 (17) | Dermatology |
| NSCLC | 79 | 48 | $1,949M | 1 | 54 (38) | Oncology |
| MM | 71 | 44 | $741M | 4 | 41 (26) | Haematology |
| rheumatoid arthritis | 64 | 16 | $1,787M | 8 | 12 (10) | Rheumatology |
| psoriatic arthritis | 56 | 24 | $2,033M | | 12 (11) | Rheumatology |
| ulcerative colitis | 54 | 37 | $1,664M | 2 | 12 (12) | Gastroenterology |
| Crohn's disease | 52 | 35 | $1,819M | 1 | 8 (7) | Gastroenterology |
| osteoporosis | 49 | 8 | $406M | 2 | 3 (2) | Endocrinology |
| phenylketonuria | 49 | 5 | $281M | | 1 (1) | Metabolic |
| melanoma | 46 | 27 | $1,865M | | 18 (16) | Oncology |
| multiple sclerosis | 45 | 24 | $691M | 3 | 17 (16) | Neurology |
| COPD | 44 | 18 | $2,565M | 1 | 3 (3) | Respiratory |
| asthma | 44 | 26 | $2,825M | 5 | 3 (3) | Respiratory |
| RCC | 42 | 17 | $1,221M | | 17 (14) | Oncology |
| ankylosing spondylitis | 39 | 15 | $1,324M | 2 | 6 (6) | Rheumatology |
| cystic fibrosis | 36 | 25 | $2,889M | 1 | 3 (3) | Rare disease |
| chronic hepatitis C | 32 | 11 | $481M | 1 | 11 (11) | Hepatology |
| prostate cancer (mCRPC) | 32 | 12 | $780M | | 11 (8) | Oncology |
| CLL | 31 | 20 | $416M | | 21 (13) | Haematology |
| HER2+ breast cancer | 31 | 13 | $467M | 1 | 11 (10) | Oncology |
| HR+/HER2- breast cancer | 31 | 18 | $372M | 2 | 17 (13) | Oncology |
| Parkinson's disease | 26 | 7 | $516M | 3 | 1 (1) | Neurology |
| hypertension | 26 | 0 | $1,999M | 20 | | Cardiovascular |
| schizophrenia | 26 | 7 | $238M | 8 | 1 (1) | Mental health |
| HIV infection | 24 | 1 | $1,554M | 1 | | Infectious disease |
| HIV-1 infection | 23 | 3 | $875M | 3 | | Infectious disease |
| atopic dermatitis | 23 | 21 | $857M | | 8 (6) | Dermatology |
| CRC | 22 | 6 | $942M | 2 | 15 (12) | Oncology |
| hidradenitis suppurativa | 19 | 12 | $417M | | 3 (2) | Rheumatology |
| ALL | 18 | 7 | $81M | 3 | 10 (8) | Haematology |
| ovarian cancer | 18 | 15 | $114M | 2 | 14 (10) | Oncology |
| pulmonary arterial hypertension | 18 | 7 | $216M | | 1 (1) | Cardiovascular |
| heart failure | 17 | 8 | $525M | 12 | 4 (4) | Cardiovascular |
| juvenile idiopathic arthritis | 17 | 7 | $412M | | 4 (2) | Rheumatology |
| chronic hepatitis B | 16 | 1 | $202M | | 5 (3) | Hepatology |
| chemotherapy-induced nausea and vomiting | 15 | 4 | $80M | 1 | | Oncology |
| chronic migraine | 15 | 11 | $211M | | 1 (1) | Neurology |
| open-angle glaucoma and ocular hypertension | 15 | 1 | $397M | | 1 (0) | Ophthalmology |
| hypercholesterolaemia | 14 | 2 | $1,291M | 2 | | Cardiovascular |
| spinal muscular atrophy | 14 | 13 | $106M | | 1 (1) | Rare disease |
| ADHD | 13 | 5 | $272M | 1 | | Neurology |
| FL | 13 | 7 | $83M | | 13 (6) | Haematology |
| breast cancer | 13 | 2 | $207M | 3 | 2 (1) | Oncology |
| dry eye syndrome | 13 | 1 | $31M | | | Ophthalmology |
| gastric cancer | 13 | 7 | $424M | 1 | 9 (5) | Oncology |
| osteoarthritis | 13 | 1 | $251M | 3 | | Rheumatology |
| AML | 12 | 9 | $123M | 3 | 14 (9) | Haematology |
| CML | 12 | 4 | $108M | 4 | 6 (5) | Haematology |
| HCC | 12 | 5 | $620M | | 8 (7) | Oncology |
| HNSCC | 12 | 9 | $872M | 1 | 5 (4) | Oncology |
| UC | 12 | 8 | $1,089M | | 10 (5) | Oncology |
| diabetic macular oedema | 12 | 7 | $747M | | 6 (6) | Ophthalmology |
| major depression | 12 | 0 | $98M | 19 | 3 (0) | Mental health |
| secondary hyperparathyroidism | 12 | 0 | $3M | | 2 (1) | Endocrinology |
| basal cell carcinoma | 11 | 2 | $18M | | 1 (0) | Dermatology |
| cervical cancer | 11 | 6 | $790M | | 6 (5) | Oncology |
| chronic severe pain | 11 | 0 | $696M | | | Pain |
| non-radiographic axial spondyloarthritis | 11 | 3 | $772M | | 5 (5) | Rheumatology |
| tyrosinaemia | 11 | 0 | $83M | | | Metabolic |
| cutaneous T-cell lymphoma | 10 | 5 | $23M | | | Haematology |
| growth hormone deficiency | 10 | 4 | $38M | 1 | 2 (2) | Endocrinology |
| hyperphosphataemia in chronic kidney disease | 10 | 1 | $35M | | | Endocrinology |
| influenza | 10 | 3 | | 5 | 2 (1) | Vaccines |
| mCRC | 10 | 6 | $571M | | 1 (0) | Oncology |
| non-valvular atrial fibrillation | 10 | 0 | $437M | | 2 (2) | Cardiovascular |
| SCLC | 9 | 7 | $333M | 2 | 7 (5) | Oncology |
| mesothelioma | 9 | 5 | $199M | | 3 (2) | Oncology |
| paroxysmal nocturnal haemoglobinuria | 9 | 3 | $188M | 1 | 5 (5) | Haematology |
| pneumococcal disease | 9 | 5 | | 1 | | Vaccines |
| ALK+ NSCLC | 8 | 6 | $56M | | 9 (8) | Oncology |
| MCL | 8 | 8 | $373M | 1 | 6 (4) | Haematology |
| age-related macular degeneration | 8 | 2 | $599M | | 1 (1) | Ophthalmology |
| chronic kidney disease | 8 | 7 | $323M | | 2 (2) | Endocrinology |
| fat malabsorption | 8 | 0 | $26M | | | Metabolic |
| herpes zoster | 8 | 4 | | 1 | | Vaccines |
| idiopathic pulmonary fibrosis | 8 | 7 | $95M | | 3 (3) | Respiratory |
| late-onset Pompe disease | 8 | 2 | | | 1 (1) | Metabolic |
| oesophageal cancer | 8 | 5 | $826M | | 3 (2) | Oncology |
| opioid dependence | 8 | 2 | $1,414M | | 2 (2) | Pain |
| primary biliary cholangitis | 8 | 6 | $31M | | 3 (3) | Hepatology |
| rotavirus gastroenteritis | 8 | 0 | | 2 | | Vaccines |
| seasonal influenza | 8 | 4 | | | | Vaccines |
| severe eosinophilic asthma | 8 | 5 | $174M | | 3 (3) | Respiratory |
| type 1 diabetes | 8 | 1 | $298M | 2 | 2 (2) | Endocrinology |
| CLL/SLL | 7 | 7 | $295M | | | Haematology |
| DLBCL | 7 | 7 | $10M | | 9 (7) | Haematology |
| Fabry disease | 7 | 4 | $15M | 1 | 1 (1) | Rare disease |
| GIST | 7 | 1 | $17M | | 1 (1) | Oncology |
| Gaucher disease type 1 | 7 | 0 | | | | Rare disease |
| TNBC | 7 | 7 | $927M | | 4 (4) | Oncology |
| Wilson disease | 7 | 3 | | | | Rare disease |
| amyotrophic lateral sclerosis | 7 | 5 | $2M | | | Neurology |
| anaphylaxis | 7 | 4 | $24M | | | Immunology |
| androgen deficiency | 7 | 1 | $17M | | | Endocrinology |
| bipolar I disorder | 7 | 0 | $117M | | 1 (1) | Mental health |
| contraception | 7 | 4 | $60M | | | Women's health |
| cystic fibrosis with Pseudomonas aeruginosa infection | 7 | 1 | $4M | | | Respiratory |
| endometrial cancer | 7 | 7 | $987M | | 5 (5) | Oncology |
| generalised myasthenia gravis | 7 | 7 | $106M | | 3 (1) | Neurology |
| macular oedema secondary to retinal vein occlusion | 7 | 3 | $240M | | 2 (2) | Ophthalmology |
| maple syrup urine disease | 7 | 0 | $69M | | | Metabolic |
| myelofibrosis | 7 | 4 | $116M | | 3 (3) | Haematology |
| postmenopausal osteoporosis | 7 | 0 | | 1 | 1 (1) | Endocrinology |
| prostate cancer | 7 | 0 | $131M | 1 | 1 (0) | Oncology |
| prostate cancer (nmCRPC) | 7 | 6 | $378M | | 4 (2) | Oncology |
| restless legs syndrome | 7 | 0 | $29M | | | Neurology |
| spasticity post-stroke | 7 | 0 | $83M | | | Neurology |
| acromegaly | 6 | 3 | $93M | | | Endocrinology |
| acute coronary syndrome | 6 | 1 | $27M | 4 | 4 (3) | Cardiovascular |
| anovulatory infertility | 6 | 2 | $140M | 1 | | Women's health |
| attention deficit hyperactivity disorder | 6 | 1 | $97M | | | Neurology |
| benign prostatic hyperplasia | 6 | 0 | $177M | 3 | 1 (0) | Urology |
| chronic hepatitis C virus infection | 6 | 5 | $157M | | | Hepatology |
| chronic iron overload | 6 | 2 | $4M | 1 | | Haematology |
| chronic pain | 6 | 2 | $341M | | | Pain |
| familial hypercholesterolaemia | 6 | 4 | $101M | | | Cardiovascular |
| heterozygous familial hypercholesterolaemia | 6 | 4 | $178M | | | Cardiovascular |
| inborn errors of protein metabolism | 6 | 0 | $42M | | | Metabolic |
| neuropathic pain | 6 | 0 | $109M | 1 | | Pain |
| post-herpetic neuralgia | 6 | 4 | | | | Vaccines |
| prostate cancer (mHSPC) | 6 | 5 | $483M | | 9 (9) | Oncology |
| relapsing-remitting multiple sclerosis | 6 | 3 | $43M | | | Neurology |
| type 1 and type 2 diabetes | 6 | 3 | $439M | | | Endocrinology |
| COVID-19 | 5 | 4 | $216M | 8 | 4 (3) | Infectious disease |
| HPV infection prevention | 5 | 1 | | | | Vaccines |
| Lennox-Gastaut syndrome | 5 | 3 | $17M | | 2 (2) | Neurology |
| RSV lower respiratory tract disease | 5 | 5 | | 1 | | Vaccines |
| atypical haemolytic uraemic syndrome | 5 | 2 | $143M | | 1 (1) | Haematology |
| cancer breakthrough pain | 5 | 1 | $15M | | | Pain |
| cancer pain | 5 | 0 | $15M | | | Pain |
| chemotherapy-induced neutropenia | 5 | 1 | $99M | | | Oncology |
| chronic hepatitis C genotype 1 | 5 | 0 | | | | Hepatology |
| glioma | 5 | 2 | $107M | | 4 (4) | Oncology |
| glucose transport protein defect | 5 | 0 | $52M | | | Metabolic |
| heart failure with reduced ejection fraction | 5 | 2 | $502M | | 3 (2) | Cardiovascular |
| hepatic encephalopathy | 5 | 1 | $20M | | 1 (1) | Hepatology |
| hereditary angioedema | 5 | 4 | $50M | 1 | 3 (3) | Rare disease |
| immune thrombocytopenic purpura | 5 | 0 | $83M | | | Haematology |
| invasive meningococcal disease | 5 | 2 | | 1 | | Vaccines |
| iron deficiency anaemia | 5 | 0 | $173M | 1 | | Other |
| overactive bladder | 5 | 0 | $80M | 4 | 1 (0) | Urology |
| pyruvate dehydrogenase deficiency | 5 | 0 | $52M | | | Metabolic |
| severe allergic asthma | 5 | 3 | $51M | | | Respiratory |
| severe obesity | 5 | 1 | $260M | | | Endocrinology |
| smoking cessation | 5 | 0 | $38M | | 1 (1) | Other |
| systemic lupus erythematosus | 5 | 5 | $1M | 1 | 2 (1) | Rheumatology |
| venous thromboembolism | 5 | 1 | $478M | 1 | 1 (1) | Cardiovascular |
| Alzheimer's disease | 4 | 0 | $12M | 2 | 1 (1) | Neurology |
| Clostridium difficile infection recurrence | 4 | 1 | | | | Infectious disease |
| Dravet syndrome | 4 | 2 | $19M | | 2 (2) | Neurology |
| GEP-NET | 4 | 2 | $41M | | | Oncology |
| Hodgkin lymphoma | 4 | 4 | $21M | | 4 (3) | Haematology |
| MDS | 4 | 2 | $90M | | 1 (0) | Haematology |
| actinic keratosis | 4 | 1 | | 2 | | Dermatology |
| anaemia of chronic kidney disease | 4 | 0 | $58M | 1 | 2 (2) | Haematology |
| autosomal dominant polycystic kidney disease | 4 | 3 | $14M | | 1 (1) | Rare disease |
| central precocious puberty | 4 | 1 | $120M | | | Endocrinology |
| chronic immune thrombocytopenic purpura | 4 | 1 | | | | Haematology |
| chronic severe disabling pain | 4 | 0 | $349M | | | Pain |
| chronic spontaneous urticaria | 4 | 2 | $51M | 1 | 1 (1) | Immunology |
| chronic stable angina | 4 | 0 | $7M | 1 | | Cardiovascular |
| cows' milk protein allergy and enteropathy | 4 | 2 | $18M | | | Metabolic |
| cryopyrin-associated periodic syndromes | 4 | 1 | $3M | | | Rare disease |
| deep vein thrombosis | 4 | 1 | $160M | | 2 (2) | Cardiovascular |
| dyslipidaemia | 4 | 0 | $357M | | | Cardiovascular |
| eosinophilic oesophagitis | 4 | 3 | $111M | | 2 (1) | Gastroenterology |
| gastrointestinal stromal tumour | 4 | 1 | $17M | | 6 (4) | Oncology |
| gastrointestinal stromal tumour (GIST) | 4 | 1 | $9M | | | Oncology |
| glioblastoma multiforme | 4 | 0 | $49M | 2 | 1 (0) | Oncology |
| hereditary angioedema (HAE) | 4 | 2 | $50M | | | Rare disease |
| homocystinuria, pyridoxine non-responsive | 4 | 0 | $49M | | | Metabolic |
| idiopathic generalised epilepsy | 4 | 2 | $47M | | | Neurology |
| inborn errors of amino acid metabolism | 4 | 0 | $17M | | | Metabolic |
| infertility (assisted reproduction) | 4 | 0 | $16M | | | Women's health |
| infertility (assisted reproductive technology) | 4 | 1 | $256M | | | Women's health |
| influenza prevention | 4 | 2 | | | | Vaccines |
| intractable partial onset epilepsy | 4 | 3 | $24M | | | Neurology |
| intractable seizures | 4 | 0 | $52M | | | Metabolic |
| lupus nephritis | 4 | 1 | $85M | | 3 (2) | Rheumatology |
| measles, mumps, rubella and varicella | 4 | 0 | | | | Vaccines |
| migraine | 4 | 1 | | 5 | 8 (8) | Neurology |
| narcolepsy | 4 | 0 | $26M | 2 | 1 (1) | Neurology |
| node-positive breast cancer | 4 | 0 | $21M | | | Oncology |
| non-familial hypercholesterolaemia with ASCVD | 4 | 2 | $63M | | | Cardiovascular |
| oesophageal squamous cell carcinoma | 4 | 3 | $86M | | 1 (1) | Oncology |
| pancreatic NET | 4 | 0 | $4M | | | Oncology |
| pancreatic neuroendocrine tumour | 4 | 1 | $27M | | | Oncology |
| peripheral T-cell lymphoma | 4 | 3 | $3M | | | Haematology |
| pneumococcal disease prevention | 4 | 2 | | | | Vaccines |
| short bowel syndrome | 4 | 3 | $22M | | 1 (1) | Gastroenterology |
| social anxiety disorder | 4 | 0 | $32M | | | Mental health |
| systemic juvenile idiopathic arthritis | 4 | 0 | $70M | | 2 (0) | Rheumatology |
| treatment-resistant depression | 4 | 4 | $3M | | 1 (0) | Mental health |
| urea cycle disorder | 4 | 3 | $1M | | | Metabolic |
| HIV-associated facial lipoatrophy | 3 | 0 | | | | Infectious disease |
| Merkel cell carcinoma | 3 | 3 | $72M | | 2 (2) | Oncology |
| Niemann-Pick Type C disease | 3 | 0 | | | | Rare disease |
| PTCL | 3 | 2 | $3M | | | Haematology |
| Prader-Willi Syndrome | 3 | 0 | $29M | | | Endocrinology |
| ROS1+ NSCLC | 3 | 3 | $6M | | | Oncology |
| SEGA associated with tuberous sclerosis | 3 | 0 | $23M | | | Rare disease |
| UC (urothelial) | 3 | 3 | $825M | | | Oncology |
| X-linked hypophosphataemia | 3 | 3 | $79M | | 1 (1) | Rare disease |
| acne vulgaris | 3 | 2 | $12M | 2 | 1 (0) | Women's health |
| acute promyelocytic leukaemia | 3 | 0 | | | 1 (1) | Haematology |
| biliary tract cancer | 3 | 3 | $176M | | 5 (4) | Oncology |
| bipolar I disorder, acute mania | 3 | 0 | $41M | | | Mental health |
| chemotherapy-induced anaemia | 3 | 0 | $191M | | | Haematology |
| cholangiocarcinoma | 3 | 3 | | 1 | 1 (1) | Oncology |
| chronic constipation | 3 | 0 | $50M | | 1 (1) | Gastroenterology |
| chronic graft versus host disease | 3 | 1 | $114M | 2 | 3 (1) | Haematology |
| chronic hepatitis D | 3 | 3 | | | 1 (1) | Hepatology |
| chronic renal failure | 3 | 0 | $36M | | | Metabolic |
| chronic rhinosinusitis with nasal polyps | 3 | 3 | $135M | | 4 (1) | Immunology |
| chronic thromboembolic pulmonary hypertension | 3 | 3 | $11M | | | Respiratory |
| classical Hodgkin's lymphoma | 3 | 2 | $761M | | 2 (1) | Haematology |
| corticosteroid-induced osteoporosis | 3 | 0 | $27M | | | Endocrinology |
| cutaneous squamous cell carcinoma | 3 | 3 | $877M | | 1 (1) | Oncology |
| differentiated thyroid carcinoma | 3 | 2 | $56M | | | Oncology |
| early pregnancy termination | 3 | 1 | | | | Women's health |
| endometriosis | 3 | 3 | $28M | 1 | 2 (2) | Women's health |
| exudative age-related macular degeneration | 3 | 0 | | | | Ophthalmology |
| focal spasticity | 3 | 0 | | | | Neurology |
| generalised anxiety disorder | 3 | 0 | $32M | | | Mental health |
| generalised convulsive status epilepticus | 3 | 3 | $2M | | | Neurology |
| giant cell arteritis | 3 | 1 | $70M | 1 | 1 (1) | Rheumatology |
| giant cell tumour of bone | 3 | 2 | $336M | | | Oncology |
| granulomatosis with polyangiitis and microscopic polyangiitis | 3 | 3 | $34M | | 1 (1) | Immunology |
| herpes simplex keratitis | 3 | 1 | $1M | | | Ophthalmology |
| hyperlipoproteinaemia type 1 | 3 | 0 | $2M | | | Metabolic |
| infertility | 3 | 1 | $123M | | | Women's health |
| lymphoma and multiple myeloma | 3 | 0 | $3M | | | Haematology |
| macular oedema secondary to CRVO | 3 | 1 | $506M | | | Ophthalmology |
| male hypogonadism | 3 | 1 | $130M | | | Endocrinology |
| metastatic colorectal cancer | 3 | 1 | $52M | | 1 (1) | Oncology |
| migraine prophylaxis | 3 | 0 | $4M | 1 | | Neurology |
| neuromyelitis optica spectrum disorder | 3 | 3 | $143M | 2 | 2 (0) | Neurology |
| nicotine dependence | 3 | 0 | $19M | 1 | | Addiction medicine |
| obstructive hypertrophic cardiomyopathy | 3 | 3 | $16M | | 1 (1) | Cardiovascular |
| opioid use disorder | 3 | 1 | $183M | | | Pain |
| pancreatic adenocarcinoma | 3 | 3 | | | | Oncology |
| pancreatic cancer | 3 | 1 | $16M | | 4 (1) | Oncology |
| partial epilepsy | 3 | 0 | $17M | | | Neurology |
| pertussis | 3 | 0 | $10M | | | Vaccines |
| polyarticular juvenile idiopathic arthritis | 3 | 0 | $312M | | | Rheumatology |
| preterm birth prevention | 3 | 1 | $10M | | | Women's health |
| severe osteoporosis | 3 | 3 | $5M | | 1 (1) | Endocrinology |
| severe psoriatic arthritis | 3 | 2 | $716M | | | Rheumatology |
| smoking cessation aid | 3 | 0 | $21M | | | Other |
| spasticity | 3 | 0 | $82M | 1 | | Neurology |
| tetanus, diphtheria, pertussis | 3 | 1 | $15M | | | Vaccines |
| urea cycle disorders | 3 | 0 | $17M | | | Metabolic |
| uterine fibroids | 3 | 1 | | | 2 (2) | Women's health |
| CMV infection/disease post-transplant | 2 | 2 | | | | Infectious disease |
| Cushing's syndrome | 2 | 2 | $1M | | | Endocrinology |
| DFSP, HES/CEL, MDS/MPD, ASM | 2 | 0 | $9M | | | Rare disease |
| Dupuytren's contracture | 2 | 1 | | | | Other |
| Friedreich's ataxia | 2 | 2 | | | 1 (0) | Rare disease |
| HER2-low breast cancer | 2 | 2 | $99M | | 1 (0) | Oncology |
| HER2-negative breast cancer | 2 | 2 | $61M | | | Oncology |
| HIV-1 pre-exposure prophylaxis | 2 | 2 | $184M | | | Infectious disease |
| HR+ breast cancer | 2 | 0 | $65M | | | Oncology |
| Hunter syndrome (MPS II) | 2 | 0 | | | | Rare disease |
| IDH-mutant glioma | 2 | 2 | | | | Oncology |
| Lambert-Eaton myasthenic syndrome | 2 | 2 | $3M | | | Neurology |
| NSAID-associated peptic ulcer | 2 | 0 | | | | Gastroenterology |
| NSCLC adenocarcinoma | 2 | 1 | $87M | | | Oncology |
| NTRK fusion solid tumours | 2 | 2 | $2M | | | Oncology |
| PMBCL | 2 | 2 | $740M | | | Haematology |
| PNH | 2 | 1 | $37M | | | Haematology |
| Paget disease of bone | 2 | 0 | $4M | | | Endocrinology |
| Waldenström macroglobulinaemia | 2 | 2 | $136M | | 1 (1) | Haematology |
| achondroplasia | 2 | 2 | $29M | | | Rare disease |
| acute severe pain | 2 | 0 | $558M | | | Pain |
| advanced breast cancer | 2 | 0 | $6M | | | Oncology |
| age-related macular degeneration with subfoveal CNV | 2 | 0 | $1M | | | Ophthalmology |
| allergic rhinitis | 2 | 2 | | 2 | | Immunology |
| alpha-mannosidosis | 2 | 2 | | | | Metabolic |
| atherosclerotic cardiovascular disease | 2 | 2 | $63M | | | Cardiovascular |
| atherosclerotic cardiovascular disease with elevated triglycerides | 2 | 2 | $1M | | | Cardiovascular |
| atrial fibrillation | 2 | 0 | $9M | 1 | 2 (1) | Cardiovascular |
| bipolar 1 disorder, acute mania | 2 | 0 | $19M | | | Mental health |
| bipolar disorder, depressive episodes | 2 | 0 | $39M | | | Mental health |
| blood glucose monitoring | 2 | 0 | | | | Other |
| bone metastases | 2 | 2 | $336M | | | Oncology |
| breast cancer bone metastases | 2 | 0 | | 1 | | Oncology |
| bronchospasm | 2 | 1 | $1M | 1 | | Respiratory |
| cerebral palsy with spasticity | 2 | 0 | $75M | | | Neurology |
| chronic constipation, neurogenic | 2 | 0 | $25M | | | Gastroenterology |
| chronic functional constipation | 2 | 0 | | | | Gastroenterology |
| chronic gout | 2 | 0 | $3M | | | Other |
| chronic hyperkalaemia | 2 | 2 | $4M | | | Endocrinology |
| chronic kidney disease stage 3-4 with hyperkalaemia | 2 | 2 | $4M | | | Metabolic |
| chronic suppurative otitis media | 2 | 0 | $5M | | | Infectious disease |
| chylothorax | 2 | 0 | $0M | | | Metabolic |
| chylous ascites | 2 | 0 | $0M | | | Metabolic |
| cow's milk allergy and food intolerance | 2 | 0 | $28M | | | Metabolic |
| cow's milk protein allergy and enteropathy | 2 | 1 | $24M | | | Metabolic |
| detrusor overactivity | 2 | 0 | | | | Urology |
| diabetic ketoacidosis | 2 | 0 | | | | Endocrinology |
| dietary management of restrictive diet conditions | 2 | 0 | $18M | | | Metabolic |
| differentiated thyroid cancer | 2 | 1 | $32M | | 2 (1) | Oncology |
| drug-resistant epilepsy | 2 | 0 | $33M | | | Metabolic |
| dry eye disease | 2 | 1 | $10M | 1 | 1 (1) | Ophthalmology |
| epilepsy, partial seizures | 2 | 0 | $69M | | | Neurology |
| faecal impaction | 2 | 0 | $50M | | | Gastroenterology |
| fibromyalgia | 2 | 0 | | | | Pain |
| functional carcinoid tumour | 2 | 2 | $81M | | | Endocrinology |
| gastroenteropancreatic neuroendocrine tumours | 2 | 2 | $41M | | | Oncology |
| glucocorticoid-induced osteoporosis | 2 | 0 | $2M | | | Endocrinology |
| glutaric aciduria type 1 | 2 | 0 | $17M | | | Metabolic |
| granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) | 2 | 1 | $24M | | | Rheumatology |
| hereditary transthyretin amyloidosis | 2 | 2 | $2M | | 1 (1) | Rare disease |
| hereditary tyrosinaemia type 1 | 2 | 2 | | | | Metabolic |
| high frequency episodic migraine | 2 | 1 | $128M | | | Neurology |
| hypercalcaemia | 2 | 0 | $0M | | | Metabolic |
| hypercalcaemia of malignancy | 2 | 0 | $340M | 1 | | Oncology |
| hypercholesterolaemia with cardiovascular risk | 2 | 0 | $115M | | | Metabolic |
| hyperphenylalaninaemia | 2 | 0 | $17M | | | Metabolic |
| hyperphosphataemia in chronic renal failure | 2 | 0 | $1M | | | Metabolic |
| hypophosphatasia | 2 | 2 | | 1 | | Metabolic |
| idiopathic menorrhagia | 2 | 0 | $59M | | | Women's health |
| idiopathic multicentric Castleman disease | 2 | 2 | $5M | | | Rare disease |
| inborn errors of metabolism | 2 | 0 | $17M | | | Metabolic |
| infantile hemangioma | 2 | 0 | $6M | | | Other |
| infertility (ART luteal phase support) | 2 | 0 | $10M | | | Women's health |
| insect venom allergy | 2 | 0 | $0M | | | Immunology |
| intermittent claudication | 2 | 0 | | 1 | 1 (0) | Cardiovascular |
| intractable partial epilepsy | 2 | 1 | $24M | | | Neurology |
| invasive fungal infection prophylaxis | 2 | 0 | $10M | | | Infectious disease |
| invasive fungal infections | 2 | 0 | $9M | | | Infectious disease |
| iron deficiency | 2 | 0 | $15M | | | Haematology |
| long chain fatty acid oxidation disorders | 2 | 0 | $0M | | | Metabolic |
| meningococcal group B disease | 2 | 2 | | | | Vaccines |
| methylmalonic acidaemia and propionic acidaemia | 2 | 0 | $17M | | | Metabolic |
| moderate-to-severe ulcerative colitis | 2 | 2 | $596M | | | Rheumatology |
| multiple cancers | 2 | 0 | $789M | 1 | | Oncology |
| myasthenia gravis | 2 | 2 | $106M | 2 | | Neurology |
| neurogenic detrusor overactivity | 2 | 0 | $73M | | 2 (0) | Urology |
| non-infectious uveitis | 2 | 2 | $242M | | 2 (2) | Ophthalmology |
| non-squamous NSCLC | 2 | 2 | $85M | | 2 (2) | Oncology |
| ocular hypertension and primary open-angle glaucoma | 2 | 0 | | | 1 (1) | Ophthalmology |
| opioid-induced constipation | 2 | 0 | | 1 | 3 (2) | Pain |
| oral contraception | 2 | 2 | $7M | | | Women's health |
| osteoarthritis of the knee | 2 | 0 | | | | Rheumatology |
| osteoarthritis or rheumatoid arthritis | 2 | 0 | $3M | | | Rheumatology |
| pain | 2 | 0 | $419M | | | Pain |
| pathologic myopia with CNV | 2 | 1 | $598M | | | Ophthalmology |
| peripheral vascular disease | 2 | 0 | $115M | | | Cardiovascular |
| plexiform neurofibroma NF1 | 2 | 2 | $4M | | | Rare disease |
| pneumococcal pneumonia and invasive pneumococcal disease | 2 | 0 | | | | Vaccines |
| polycythemia vera | 2 | 2 | $124M | | | Infectious disease |
| premenstrual dysphoric disorder | 2 | 2 | $7M | | | Women's health |
| primary progressive multiple sclerosis | 2 | 2 | $249M | | 1 (1) | Neurology |
| primary pulmonary arterial hypertension | 2 | 0 | | | | Respiratory |
| primary pulmonary hypertension | 2 | 0 | $6M | | | Respiratory |
| progressive familial intrahepatic cholestasis | 2 | 2 | | | | Hepatology |
| prostate cancer (nmHSPC) | 2 | 2 | $180M | | | Oncology |
| pruritus associated with chronic kidney disease | 2 | 2 | $1M | | | Rare disease |
| pulmonary hypertension | 2 | 0 | $2M | 2 | | Respiratory |
| radioactive iodine refractory differentiated thyroid cancer | 2 | 0 | $31M | | | Oncology |
| rheumatoid arthritis or plaque psoriasis | 2 | 2 | $20M | | | Rheumatology |
| secondary progressive multiple sclerosis | 2 | 1 | $13M | | | Neurology |
| severe chronic plaque psoriasis | 2 | 1 | $658M | | | Rheumatology |
| severe cystic acne | 2 | 0 | $5M | | | Dermatology |
| severe dry eye syndrome | 2 | 0 | $9M | | | Ophthalmology |
| severe plaque psoriasis | 2 | 2 | $596M | | | Rheumatology |
| severe primary axillary hyperhidrosis | 2 | 0 | $73M | | | Dermatology |
| soft tissue sarcoma | 2 | 0 | $9M | 1 | 1 (1) | Oncology |
| solar keratosis | 2 | 0 | $2M | | | Dermatology |
| spinal muscular atrophy type 1 | 2 | 2 | $1M | | | Rare disease |
| squamous NSCLC | 2 | 2 | $85M | | 4 (2) | Oncology |
| squamous cell anal carcinoma | 2 | 2 | | | | Oncology |
| stable angina pectoris | 2 | 0 | | 1 | | Cardiovascular |
| superficial basal cell carcinoma | 2 | 0 | | | | Dermatology |
| systemic light-chain AL amyloidosis | 2 | 2 | $225M | | | Haematology |
| systemic mycoses | 2 | 1 | $1M | | | Infectious disease |
| thyroid hormone deficiency | 2 | 1 | | | | Endocrinology |
| transthyretin amyloid cardiomyopathy | 2 | 2 | $137M | | | Cardiovascular |
| transthyretin cardiac amyloidosis | 2 | 2 | $137M | | | Cardiovascular |
| type 1 and type 2 diabetes mellitus | 2 | 0 | $75M | | | Endocrinology |
| type 2 diabetes with dyslipidaemia | 2 | 0 | | | | Cardiovascular |
| unresectable advanced or metastatic cancer | 2 | 1 | $939M | | | Oncology |
| urge urinary incontinence | 2 | 0 | $7M | | | Urology |
| vasomotor symptoms, menopause | 2 | 2 | | | 1 (1) | Women's health |
| vitreomacular traction | 2 | 0 | | | | Ophthalmology |
| AMD with subfoveal CNV | 1 | 1 | $1M | | | Ophthalmology |
| ATTR cardiomyopathy | 1 | 1 | $137M | | | Rare disease |
| Alagille syndrome | 1 | 1 | | | | Hepatology |
| Alzheimer's dementia with BPSD | 1 | 0 | $21M | | | Neurology |
| Alzheimer's disease dementia with psychosis/agitation/aggression | 1 | 1 | $21M | | | Mental health |
| B-cell precursor ALL | 1 | 1 | $33M | | | Haematology |
| B-cell precursor acute lymphoblastic leukaemia | 1 | 0 | $33M | | | Haematology |
| Buruli ulcer | 1 | 0 | $0M | | | Infectious disease |
| CD20+ lymphoid cancer (NHL, CLL, ALL) | 1 | 0 | $24M | | | Haematology |
| CD20+ lymphoid cancers | 1 | 0 | $24M | | | Haematology |
| CD30+ peripheral T-cell lymphoma | 1 | 1 | $21M | | | Haematology |
| CLL or small lymphocytic lymphoma | 1 | 1 | $136M | | | Haematology |
| CML and Ph+ ALL | 1 | 1 | $5M | | | Haematology |
| CML, Ph+ ALL, and other haematologic and solid malignancies | 1 | 0 | $9M | | | Haematology |
| CMV infection prophylaxis | 1 | 1 | | | | Infectious disease |
| CMV infection prophylaxis post-HSCT | 1 | 1 | | | | Infectious disease |
| EGFR mutation-positive NSCLC | 1 | 1 | $201M | | | Oncology |
| ES-SCLC | 1 | 1 | $157M | | | Oncology |
| HER2- breast cancer | 1 | 1 | $61M | | 1 (1) | Oncology |
| HIV | 1 | 0 | $176M | | | Infectious disease |
| HIV infection prevention | 1 | 1 | $184M | | | Infectious disease |
| HIV pre-exposure prophylaxis | 1 | 0 | $176M | | | Infectious disease |
| HIV prevention | 1 | 0 | $184M | | | Infectious disease |
| HIV-1 infection prevention | 1 | 1 | $184M | | | Infectious disease |
| HIV-1 infection, multidrug-resistant | 1 | 1 | | | | Infectious disease |
| HPV prevention | 1 | 0 | | | | Vaccines |
| HPV-related infection and disease | 1 | 0 | | | | Vaccines |
| HR+/HER2-low breast cancer | 1 | 1 | $99M | | 1 (0) | Oncology |
| HR- breast cancer | 1 | 0 | $61M | | | Oncology |
| Haemophilus influenzae and Neisseria meningitis serogroup C prevention | 1 | 0 | | | | Vaccines |
| Hepatitis B, Hepatitis C, and HIV | 1 | 0 | | | | Infectious disease |
| Huntington's disease | 1 | 1 | | | | Neurology |
| LS-SCLC | 1 | 1 | $176M | | | Oncology |
| MCL, WM, CLL, SLL | 1 | 1 | $136M | | | Haematology |
| MDS and CMML | 1 | 1 | $12M | | | Haematology |
| MDS with del(5q) | 1 | 0 | $79M | | 1 (1) | Haematology |
| MDS, CMML, AML | 1 | 0 | $11M | | 1 (1) | Haematology |
| MM/lymphoma stem cell mobilisation | 1 | 1 | $3M | | | Haematology |
| MRSS and VRE infection | 1 | 0 | | | | Infectious disease |
| MSI-H CRC | 1 | 1 | $199M | | | Oncology |
| MSUD, tyrosinaemia, homocystinuria | 1 | 0 | $17M | | | Metabolic |
| NHL | 1 | 0 | $24M | 2 | | Haematology |
| NHL, CLL, RA, GPA, MPA, CD20+ ALL | 1 | 0 | $24M | | | Haematology |
| NHL, HL, MM | 1 | 0 | $3M | | | Haematology |
| NSCLC or STS with NTRK fusions | 1 | 1 | $2M | | | Oncology |
| NTRK gene fusion solid tumours | 1 | 1 | $2M | | | Oncology |
| Non-Hodgkin's lymphoma, CLL, rheumatoid arthritis, granulomatosis with polyangiitis, microscopic polyangiitis | 1 | 1 | $24M | | | Haematology |
| PAH secondary to connective tissue disease | 1 | 0 | $6M | | | Cardiovascular |
| Pompe disease | 1 | 1 | | | 1 (1) | Rare disease |
| Pompe disease, infantile-onset | 1 | 0 | | | | Rare disease |
| RAI-R DTC | 1 | 1 | $31M | | | Oncology |
| RAI-refractory differentiated thyroid cancer | 1 | 1 | $1M | | | Oncology |
| RET fusion-positive NSCLC | 1 | 1 | $1M | | | Oncology |
| RSV lower respiratory tract illness | 1 | 1 | | | | Vaccines |
| RSV lower respiratory tract infection prevention | 1 | 1 | | | | Vaccines |
| SMA (infantile-onset and childhood-onset) | 1 | 1 | $55M | | | Neurology |
| SMA with 3 copies SMN2 gene | 1 | 1 | $55M | | | Rare disease |
| Smith-Magenis Syndrome insomnia | 1 | 1 | $0M | | | Neurology |
| TSH-responsive thyroid tumour | 1 | 1 | | | | Endocrinology |
| VHL disease-associated RCC, CNS haemangioblastomas, pNET | 1 | 1 | $6M | | | Oncology |
| VIPoma | 1 | 0 | $9M | | | Endocrinology |
| VTE prevention in joint replacement | 1 | 0 | $309M | | | Cardiovascular |
| Waldenström macroglobulinemia | 1 | 0 | $136M | | | Haematology |
| aHUS | 1 | 1 | $37M | | | Rare disease |
| acid sphingomyelinase deficiency | 1 | 1 | | | | Rare disease |
| acquired thrombotic thrombocytopenic purpura | 1 | 0 | | | | Haematology |
| acromegaly and functional carcinoid tumour | 1 | 0 | | | | Endocrinology |
| acromegaly, functional carcinoid tumour, GEP-NET | 1 | 1 | $41M | | | Endocrinology |
| actinic keratosis, basal cell carcinoma, external genital warts | 1 | 0 | $2M | | | Dermatology |
| activated PI3Kδ syndrome | 1 | 1 | | | | Rare disease |
| acute and chronic pain | 1 | 1 | $101M | | | Pain |
| acute dystonic reaction | 1 | 0 | | | | Neurology |
| acute hepatic porphyria | 1 | 1 | | | | Hepatology |
| acute hyperammonaemia (organic acidaemias) | 1 | 0 | | | | Metabolic |
| acute pain | 1 | 0 | $1M | 1 | | Pain |
| adrenal insufficiency | 1 | 1 | $5M | | | Endocrinology |
| adult growth hormone deficiency | 1 | 0 | $29M | | | Endocrinology |
| advanced breast cancer / CRC / NSCLC | 1 | 0 | $2M | | | Oncology |
| advanced or metastatic cancers | 1 | 1 | $740M | | | Oncology |
| advanced systemic mastocytosis | 1 | 1 | $11M | | 2 (2) | Haematology |
| age-related macular degeneration (nAMD) | 1 | 1 | $506M | | | Ophthalmology |
| age-related macular degeneration with choroidal neovascularisation | 1 | 0 | | | | Ophthalmology |
| alcohol use disorder | 1 | 0 | | 1 | | Mental health |
| allograft rejection prevention | 1 | 0 | $42M | | | Immunology |
| androgen deficiency (transgender/intersex) | 1 | 0 | $8M | | | Endocrinology |
| anovulatory infertility / polycystic ovarian disease | 1 | 0 | $27M | | | Women's health |
| anovulatory infertility and controlled ovarian stimulation | 1 | 1 | $113M | | | Women's health |
| anticoagulation | 1 | 0 | $32M | | | Cardiovascular |
| antimicrobial stewardship | 1 | 0 | $93M | | | Infectious disease |
| assisted reproductive technique support | 1 | 1 | $1M | | | Women's health |
| asthma or COPD with bronchospasm | 1 | 1 | $62M | | | Respiratory |
| autism with severe behavioural disturbances | 1 | 0 | $21M | | | Mental health |
| axillary hyperhidrosis | 1 | 0 | $73M | | | Dermatology |
| bacterial infection | 1 | 0 | $8M | | | Infectious disease |
| bacterial infection (tonsillitis, pharyngitis, otitis media) | 1 | 0 | | | | Infectious disease |
| bipolar I disorder, acute mania or mixed episodes | 1 | 0 | $2M | | | Mental health |
| bisphosphonate-refractory hypercalcaemia of malignancy | 1 | 1 | $336M | | | Oncology |
| blastic plasmacytoid dendritic cell neoplasm | 1 | 1 | | | 1 (0) | Haematology |
| blepharospasm, hemifacial spasm, spasmodic torticollis, cerebral palsy spasticity | 1 | 0 | $5M | | | Neurology |
| bone metastases (breast cancer, mCRPC) | 1 | 0 | $4M | | | Oncology |
| bone metastases from breast cancer and prostate cancer | 1 | 0 | $336M | | | Oncology |
| branch retinal vein occlusion with macular oedema | 1 | 0 | $134M | | | Ophthalmology |
| breast cancer prevention | 1 | 1 | $1M | | | Oncology |
| cancer pain (breakthrough, palliative) | 1 | 1 | $8M | | | Pain |
| carcinoid syndrome | 1 | 0 | $41M | | | Endocrinology |
| carcinoid tumour | 1 | 0 | $9M | | | Endocrinology |
| cardiac allograft rejection | 1 | 0 | $42M | | | Other |
| cardiovascular disease with obesity | 1 | 1 | $260M | | | Cardiovascular |
| cerebral palsy with upper limb spasticity | 1 | 0 | $73M | | | Neurology |
| cerebral palsy, focal spasticity | 1 | 0 | $5M | | | Neurology |
| cervical dystonia, blepharospasm, post-stroke upper limb spasticity | 1 | 0 | | | | Neurology |
| chemotherapy-induced neutropenia, peripheral blood progenitor cell mobilisation, severe congenital neutropenia, severe chronic neutropenia, chronic cyclical neutropenia | 1 | 0 | $5M | | | Haematology |
| choroidal neovascularisation (non-AMD, non-PM) | 1 | 1 | $92M | | | Ophthalmology |
| chromoblastomycosis | 1 | 0 | $9M | | | Infectious disease |
| chronic breathlessness | 1 | 0 | | | | Pain |
| chronic coronary artery disease and peripheral artery disease | 1 | 0 | $128M | | | Cardiovascular |
| chronic disease and HIV | 1 | 0 | | | | Other |
| chronic hand eczema | 1 | 1 | | | 1 (1) | Dermatology |
| chronic hepatitis B and C | 1 | 1 | $11M | | | Infectious disease |
| chronic hepatitis B with advanced liver disease | 1 | 0 | | | | Hepatology |
| chronic hypoparathyroidism | 1 | 1 | | | | Endocrinology |
| chronic idiopathic urticaria | 1 | 1 | $51M | | | Dermatology |
| chronic kidney disease with cardiovascular risk | 1 | 0 | $65M | | | Cardiovascular |
| chronic kidney disease with hyperkalaemia | 1 | 1 | $4M | | | Endocrinology |
| chronic kidney disease with type 2 diabetes | 1 | 1 | $4M | | 1 (1) | Endocrinology |
| chronic pain in palliative care | 1 | 1 | $183M | | | Pain |
| chronic pain unresponsive to non-opioid analgesia | 1 | 1 | $164M | | | Pain |
| chronic pouchitis | 1 | 1 | $183M | | | Gastroenterology |
| chronic sialorrhea | 1 | 1 | | | | Neurology |
| chronic symptomatic gout | 1 | 0 | $3M | | | Rheumatology |
| climacteric symptoms | 1 | 0 | $22M | | | Women's health |
| coccidioidomycosis | 1 | 0 | $9M | | | Infectious disease |
| complement 3 glomerulopathy | 1 | 1 | | | 1 (0) | Rare disease |
| complement 3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis | 1 | 1 | $8M | | | Rare disease |
| complex refractory fistulising Crohn's disease | 1 | 1 | $538M | | | Gastroenterology |
| controlled ovarian hyperstimulation | 1 | 1 | $113M | 1 | | Women's health |
| coronary artery disease / peripheral artery disease | 1 | 1 | $128M | | | Cardiovascular |
| cow's milk protein allergy and related enteropathies | 1 | 1 | $24M | | | Metabolic |
| cranial diabetes insipidus and primary nocturnal enuresis | 1 | 0 | $5M | | | Endocrinology |
| dMMR colorectal cancer | 1 | 1 | $740M | | | Oncology |
| deep vein thrombosis prophylaxis and treatment | 1 | 0 | | | | Cardiovascular |
| dermatitis herpetiformis | 1 | 0 | $3M | | | Dermatology |
| dermatofibrosarcoma protuberans, CEL/HES, MDS/MPN, systemic mastocytosis | 1 | 0 | $9M | | | Haematology |
| dermatophyte infection | 1 | 0 | $1M | | | Dermatology |
| diabetes | 1 | 0 | | | | Endocrinology |
| diabetic kidney disease | 1 | 1 | $4M | | | Endocrinology |
| dietary management - ketogenic diet and inborn errors of metabolism | 1 | 0 | $17M | | | Metabolic |
| dietary management of medium chain triglyceride malabsorption | 1 | 0 | $2M | | | Metabolic |
| dietary management of metabolic and gastrointestinal disorders | 1 | 0 | $0M | | | Metabolic |
| dietary management with vitamin/mineral supplementation | 1 | 0 | $18M | | | Metabolic |
| dietary management, reduced mobility | 1 | 0 | $18M | | | Metabolic |
| diphtheria, tetanus, pertussis prevention | 1 | 0 | | | | Vaccines |
| diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis immunisation | 1 | 1 | $5M | | | Vaccines |
| diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, Haemophilus influenzae type b | 1 | 0 | | | | Vaccines |
| drug-resistant partial epilepsy | 1 | 0 | $9M | | | Neurology |
| dry eye disease with keratitis | 1 | 1 | $10M | | | Ophthalmology |
| early stage breast cancer | 1 | 1 | $4M | | | Oncology |
| early symptomatic Alzheimer's disease | 1 | 1 | | | | Neurology |
| endogenous Cushing's syndrome | 1 | 1 | $1M | | | Endocrinology |
| epilepsy | 1 | 0 | $1M | 8 | | Neurology |
| episodic migraine | 1 | 1 | $48M | | | Neurology |
| essential thrombocythemia | 1 | 1 | $11M | | | Infectious disease |
| estrogen deficiency | 1 | 1 | $32M | | | Women's health |
| familial Mediterranean fever | 1 | 1 | | | | Rare disease |
| familial homozygous hypercholesterolaemia | 1 | 0 | $63M | | 1 (1) | Cardiovascular |
| fat malabsorption and metabolic disorders | 1 | 0 | $2M | | | Metabolic |
| fat malabsorption and related disorders | 1 | 0 | | | | Metabolic |
| febrile neutropenia prophylaxis | 1 | 0 | $4M | | | Oncology |
| fibrodysplasia ossificans progressiva | 1 | 1 | | | | Rare disease |
| focal spasticity after stroke | 1 | 1 | $73M | | | Neurology |
| focal spasticity post-stroke | 1 | 1 | | | | Neurology |
| food allergies and intolerances | 1 | 0 | | | | Metabolic |
| fungal or yeast infection | 1 | 0 | $1M | | | Dermatology |
| fusariosis | 1 | 0 | $9M | | | Infectious disease |
| gBRCAm HER2- breast cancer | 1 | 1 | $0M | | | Oncology |
| gastro-oesophageal reflux disease | 1 | 0 | $22M | 3 | | Gastroenterology |
| gastroenteropancreatic neuroendocrine tumours (GEP-NETs) | 1 | 1 | $41M | | | Oncology |
| geographic atrophy secondary to AMD | 1 | 1 | | | | Ophthalmology |
| geographic atrophy secondary to age-related macular degeneration | 1 | 1 | $8M | | | Ophthalmology |
| glioblastoma | 1 | 1 | $49M | | | Oncology |
| glutaric aciduria type 1 / pyridoxine dependent epilepsy | 1 | 0 | $17M | | | Metabolic |
| graft-versus-host disease | 1 | 1 | $113M | | | Haematology |
| hepatitis B | 1 | 0 | | | | Vaccines |
| hepatitis C genotype 1 | 1 | 1 | $157M | | | Hepatology |
| hereditary angioedema (HAE) with C1-esterase inhibitor deficiency | 1 | 0 | $2M | | | Rare disease |
| herpes zoster and postherpetic neuralgia | 1 | 0 | | | | Vaccines |
| homocystinuria | 1 | 0 | $1M | | | Metabolic |
| hypercholesterolaemia and ASCVD | 1 | 1 | $38M | | | Cardiovascular |
| hyperphenylalaninaemia (BH4-deficient) | 1 | 0 | $17M | | | Metabolic |
| hyperphosphataemia in CKD | 1 | 0 | $10M | | | Endocrinology |
| hyperphosphataemia in CKD on dialysis | 1 | 0 | $10M | | | Endocrinology |
| hypertension and stable coronary heart disease | 1 | 0 | $112M | | | Cardiovascular |
| hypertension and/or angina | 1 | 0 | $225M | | | Cardiovascular |
| hypoactive sexual desire dysfunction | 1 | 1 | $8M | | | Women's health |
| hypogonadism | 1 | 0 | $8M | | | Endocrinology |
| hypoparathyroidism | 1 | 1 | | | 1 (0) | Endocrinology |
| hypovolaemia | 1 | 0 | | | | Other |
| iNHL and MCL | 1 | 1 | $7M | | | Haematology |
| idiopathic overactive bladder | 1 | 0 | $73M | | | Urology |
| immune thrombocytopaenia | 1 | 0 | $15M | | | Haematology |
| immune-mediated inflammatory diseases (paediatric) | 1 | 1 | $242M | | | Rheumatology |
| inborn errors of fat metabolism | 1 | 0 | $7M | | | Metabolic |
| indolent NHL and MCL | 1 | 1 | $7M | | | Haematology |
| infantile haemangioma | 1 | 0 | $6M | | | Other |
| infantile spasms | 1 | 0 | | | | Neurology |
| infantile spasms and hypsarrhythmia | 1 | 0 | $0M | | | Neurology |
| infantile spasms/hypsarrhythmia and multiple sclerosis | 1 | 0 | $0M | | | Neurology |
| infertility (ART luteal support) | 1 | 0 | $10M | | | Women's health |
| infertility (ART) | 1 | 1 | $4M | | | Women's health |
| infertility (luteal phase support) | 1 | 0 | $10M | | | Women's health |
| infertility (severe LH deficiency) | 1 | 1 | $125M | | | Women's health |
| influenza A and B | 1 | 0 | | 1 | | Infectious disease |
| insomnia in autism spectrum disorder and smith-magenis syndrome | 1 | 0 | | | | Neurology |
| intractable epilepsy | 1 | 0 | $15M | | | Neurology |
| intractable partial onset seizures | 1 | 0 | | | | Neurology |
| intractable seizures with metabolic disorders | 1 | 0 | $18M | | | Metabolic |
| intractable seizures, glucose transport protein defect, pyruvate dehydrogenase deficiency | 1 | 0 | | | | Metabolic |
| invasive aspergillosis | 1 | 0 | $9M | 1 | | Infectious disease |
| invasive meningococcal disease (group B) | 1 | 1 | | 1 | | Vaccines |
| invasive meningococcal disease (serogroups A, C, W-135, Y) | 1 | 1 | | | | Vaccines |
| iron and folic acid deficiency | 1 | 0 | $4M | | | Metabolic |
| isovaleric acidaemia | 1 | 0 | $5M | | | Metabolic |
| ketogenic diet management | 1 | 0 | $18M | | | Metabolic |
| ketogenic diet-responsive seizures | 1 | 0 | $0M | | | Metabolic |
| lactose intolerance | 1 | 0 | | | | Other |
| leiomyosarcoma | 1 | 1 | $1M | | | Oncology |
| liposarcoma | 1 | 0 | $3M | | | Oncology |
| liver failure | 1 | 0 | $2M | | | Metabolic |
| low-grade NHL | 1 | 0 | $4M | | | Haematology |
| low-grade non-Hodgkin's lymphoma | 1 | 0 | $4M | | | Haematology |
| lung allograft rejection | 1 | 0 | $42M | | | Other |
| lymphoma and MM | 1 | 0 | $3M | | | Haematology |
| lysosomal acid lipase deficiency | 1 | 1 | | | 1 (0) | Metabolic |
| mTNBC | 1 | 1 | $157M | | | Oncology |
| macular oedema secondary to BRVO | 1 | 0 | $506M | | | Ophthalmology |
| malnutrition and enteral nutrition intolerance | 1 | 0 | $2M | | | Metabolic |
| maternal phenylketonuria | 1 | 1 | $17M | | | Metabolic |
| medical nutritional product | 1 | 0 | $7M | | | Metabolic |
| medullary thyroid cancer | 1 | 1 | $1M | 1 | 2 (1) | Oncology |
| menopausal vasomotor symptoms | 1 | 1 | $32M | | | Women's health |
| metabolic disorders requiring MCT | 1 | 0 | $2M | | | Metabolic |
| metastatic colorectal cancer and non-small cell lung cancer | 1 | 0 | $49M | | | Oncology |
| mucopolysaccharidosis IVA | 1 | 1 | | | | Metabolic |
| mucopolysaccharidosis type IVA | 1 | 1 | | | | Rare disease |
| mucopolysaccharidosis type VI | 1 | 0 | | | | Rare disease |
| multiple PBS-reimbursed indications | 1 | 1 | $720M | | | Rheumatology |
| multiple advanced cancers | 1 | 1 | $85M | | | Oncology |
| multiple autoimmune and inflammatory conditions | 1 | 1 | $242M | | | Rheumatology |
| multiple autoimmune conditions | 1 | 1 | $242M | | | Rheumatology |
| multiple immune-mediated inflammatory diseases | 1 | 1 | $242M | | | Rheumatology |
| multiple monosaccharide intolerance | 1 | 0 | $17M | | | Metabolic |
| muscle overactivity and spasticity | 1 | 0 | $73M | | | Neurology |
| muscle-invasive bladder cancer | 1 | 1 | $176M | | 1 (1) | Oncology |
| mycetoma | 1 | 0 | $9M | | | Infectious disease |
| mycosis fungoides cutaneous T-cell lymphoma | 1 | 1 | $0M | | | Dermatology |
| mycosis fungoides-type CTCL | 1 | 1 | $0M | | | Dermatology |
| myelofibrosis, polycythemia vera, acute graft versus host disease, chronic graft versus host disease | 1 | 1 | $113M | | | Haematology |
| myopic CNV | 1 | 0 | $506M | | | Ophthalmology |
| narcolepsy with excessive daytime sleepiness | 1 | 1 | $7M | | | Neurology |
| nasopharyngeal carcinoma | 1 | 1 | | | | Oncology |
| neovascular AMD, diabetic macular oedema, macular oedema secondary to RVO | 1 | 0 | $92M | | | Ophthalmology |
| neovascular age-related macular degeneration | 1 | 1 | $134M | | | Ophthalmology |
| neuroblastoma | 1 | 1 | | | 1 (1) | Oncology |
| neuroendocrine tumour (midgut) | 1 | 0 | $9M | | | Oncology |
| neuroendocrine tumours (pNET/epNET) | 1 | 1 | $56M | | | Oncology |
| neuronal ceroid lipofuscinosis type 2 | 1 | 1 | | | | Rare disease |
| neuropathic pain and partial seizures | 1 | 0 | $54M | | | Pain |
| non-familial hypercholesterolaemia | 1 | 1 | | | | Cardiovascular |
| nutritional supplementation | 1 | 0 | $24M | | | Metabolic |
| obesity | 1 | 1 | $260M | 2 | 2 (1) | Metabolic |
| oesophago-gastric cancer | 1 | 0 | $1M | | | Oncology |
| open angle glaucoma | 1 | 0 | $16M | | | Ophthalmology |
| opioid overdose | 1 | 1 | $107M | | | Pain |
| oral squamous cell carcinoma | 1 | 1 | $43M | | | Oncology |
| organ transplant rejection | 1 | 0 | $42M | | | Immunology |
| organ transplant rejection prophylaxis | 1 | 0 | $23M | 1 | | Immunology |
| organ/tissue transplant rejection | 1 | 0 | $42M | | | Immunology |
| osteoporosis prevention | 1 | 1 | $32M | | 1 (0) | Women's health |
| pain (non-oncology and cancer) | 1 | 0 | $14M | | | Pain |
| pain and fever | 1 | 0 | $82M | | | Pain |
| palliative care | 1 | 0 | | | | Pain |
| pancreatic exocrine insufficiency | 1 | 0 | $31M | 1 | | Gastroenterology |
| penicillin-sensitive infections | 1 | 0 | $3M | | | Infectious disease |
| peripheral artery disease with cardiovascular disease | 1 | 1 | $128M | | | Cardiovascular |
| pertussis prophylaxis in pregnancy | 1 | 1 | $5M | | | Vaccines |
| phenylketonuria (BH4-deficient) | 1 | 0 | $17M | | | Metabolic |
| phenylketonuria (PKU) | 1 | 1 | | | | Metabolic |
| phenylketonuria (PKU) / hyperphenylalaninaemia | 1 | 0 | | | | Metabolic |
| phenylketonuria nutritional support | 1 | 0 | $17M | | | Metabolic |
| plaque psoriasis, severe recalcitrant | 1 | 1 | $20M | | | Rheumatology |
| policy decision - OTC PBS removal | 1 | 1 | | | | Other |
| polycythaemia vera | 1 | 1 | $113M | | 1 (1) | Haematology |
| post-menopausal osteoporosis | 1 | 0 | $336M | | | Endocrinology |
| post-stroke upper limb spasticity | 1 | 0 | $5M | | | Neurology |
| posterior uveitis | 1 | 1 | $15M | | | Ophthalmology |
| postoperative eye inflammation | 1 | 0 | $24M | | | Ophthalmology |
| postoperative nausea and vomiting | 1 | 0 | $0M | | | Oncology |
| premature ovarian failure | 1 | 0 | $61M | | | Women's health |
| primary axillary hyperhidrosis | 1 | 1 | $57M | | 1 (1) | Dermatology |
| primary biliary cirrhosis | 1 | 0 | $18M | | | Hepatology |
| primary cardiovascular prevention in CKD | 1 | 0 | $65M | | | Cardiovascular |
| primary hypercholesterolaemia | 1 | 0 | $65M | 1 | 2 (2) | Cardiovascular |
| primary hypercholesterolemia / mixed hyperlipidemia / homozygous familial hypercholesterolemia | 1 | 0 | $65M | | | Cardiovascular |
| primary hyperoxaluria type 1 | 1 | 1 | | | | Rare disease |
| primary hyperparathyroidism | 1 | 0 | $1M | | | Endocrinology |
| primary insulin-like growth factor 1 deficiency | 1 | 0 | $0M | | | Endocrinology |
| progressive fibrosing ILD | 1 | 1 | $87M | | | Respiratory |
| progressive fibrosing interstitial lung disease | 1 | 1 | $87M | | | Respiratory |
| proliferative diabetic retinopathy | 1 | 1 | $92M | | | Ophthalmology |
| prostate cancer (CRPC) | 1 | 0 | $214M | | | Oncology |
| prostate cancer (mHRPC) | 1 | 0 | $2M | | | Oncology |
| prostate cancer (mHSPC / nmCRPC) | 1 | 1 | $51M | | | Oncology |
| prostate cancer / central precocious puberty | 1 | 1 | $57M | | | Oncology |
| pulmonary embolism | 1 | 0 | $128M | 1 | 1 (1) | Cardiovascular |
| pyridoxine-dependent epilepsy | 1 | 1 | $17M | | | Metabolic |
| recurrent orolabial herpes in HIV | 1 | 0 | $5M | | | Infectious disease |
| recurrent orolabial herpes in HIV infection | 1 | 0 | $5M | | | Infectious disease |
| recurrent venous thromboembolism | 1 | 0 | $128M | | | Cardiovascular |
| refractory partial epilepsy | 1 | 0 | $2M | | | Neurology |
| rheumatoid arthritis, severe recalcitrant | 1 | 1 | $20M | | | Rheumatology |
| sALCL | 1 | 1 | $21M | | | Haematology |
| scabies | 1 | 0 | $3M | | | Dermatology |
| scalp psoriasis | 1 | 0 | $1M | | | Dermatology |
| secondary hyperparathyroidism / primary hyperparathyroidism / parathyroid carcinoma | 1 | 0 | $1M | | | Endocrinology |
| secondary prevention after myocardial infarction | 1 | 0 | | | | Cardiovascular |
| severe Crohn's disease | 1 | 1 | $538M | | | Gastroenterology |
| severe LH and FSH deficiency | 1 | 0 | $125M | | | Women's health |
| severe acne vulgaris | 1 | 0 | $2M | | | Dermatology |
| severe aplastic anaemia | 1 | 0 | $27M | | 1 (0) | Haematology |
| severe asthma | 1 | 1 | $51M | | | Immunology |
| severe asthma, severe allergic asthma, chronic spontaneous urticaria | 1 | 1 | | | | Respiratory |
| severe chronic plaque psoriasis, severe psoriatic arthritis, ankylosing spondylitis | 1 | 0 | | | | Dermatology |
| severe corticosteroid-responsive dermatoses | 1 | 1 | $1M | | | Dermatology |
| severe disabling pain | 1 | 0 | $2M | | | Pain |
| severe established osteoporosis | 1 | 0 | | | | Endocrinology |
| severe established vertebral osteoporosis | 1 | 0 | $2M | | | Endocrinology |
| severe luteinising hormone deficiency | 1 | 1 | $51M | | | Women's health |
| severe pain | 1 | 0 | | 1 | | Pain |
| severe primary IGF-1 deficiency | 1 | 1 | $0M | | | Endocrinology |
| severe psoriatic arthritis, ankylosing spondylitis, severe active rheumatoid arthritis, severe chronic plaque psoriasis, severe active juvenile idiopathic arthritis | 1 | 0 | $80M | | | Rheumatology |
| severe rheumatoid arthritis | 1 | 1 | $58M | | | Rheumatology |
| severe uncontrolled asthma | 1 | 1 | | | | Respiratory |
| short bowel syndrome with intestinal failure | 1 | 1 | $13M | | | Gastroenterology |
| short stature associated with chronic renal insufficiency | 1 | 0 | $29M | | | Endocrinology |
| spasticity (lower limb post-stroke/TBI) | 1 | 1 | $5M | | | Neurology |
| spinal muscular atrophy type I | 1 | 1 | $1M | | | Rare disease |
| stable angina | 1 | 0 | $3M | | | Cardiovascular |
| stable coronary artery disease or peripheral artery disease | 1 | 1 | $128M | | | Cardiovascular |
| staphylococcus aureus nasal colonisation | 1 | 0 | $1M | | | Infectious disease |
| systemic anaplastic large cell lymphoma | 1 | 1 | $21M | | | Haematology |
| thalassaemia major with transfusional iron overload | 1 | 0 | $1M | | | Rare disease |
| thrombo-embolic disorder prevention | 1 | 1 | $32M | | | Cardiovascular |
| thrombocytopenia in chronic hepatitis C | 1 | 0 | $27M | | | Infectious disease |
| thromboembolic disorder prevention and treatment | 1 | 0 | $32M | | | Cardiovascular |
| thyroid cancer | 1 | 0 | $2M | | 1 (1) | Endocrinology |
| thyroid cancer post-thyroidectomy | 1 | 0 | $2M | | | Endocrinology |
| thyroid eye disease | 1 | 1 | | | | Endocrinology |
| thyroid remnant ablation | 1 | 0 | | | | Endocrinology |
| tobacco smoking cessation | 1 | 0 | $10M | | | Other |
| tobacco smoking cessation aid | 1 | 0 | $10M | | | Other |
| treatment-refractory bipolar I disorder | 1 | 0 | $21M | | | Mental health |
| treatment-resistant major depression | 1 | 0 | $19M | | | Mental health |
| tuberous sclerosis complex-associated refractory seizures | 1 | 1 | $23M | | | Neurology |
| type 1 diabetes mellitus | 1 | 0 | $73M | | | Endocrinology |
| type 2 asthma | 1 | 1 | $491M | | | Respiratory |
| type 2 diabetes mellitus | 1 | 0 | $73M | | | Endocrinology |
| type 2 diabetes with obesity | 1 | 0 | | | | Endocrinology |
| ulcerative colitis and Crohn's disease | 1 | 0 | $487M | | | Gastroenterology |
| ulcerative proctitis | 1 | 1 | $102M | | | Gastroenterology |
| upper limb spasticity post-acute neurological injury | 1 | 1 | $5M | | | Neurology |
| upper limb spasticity post-stroke/TBI/SCI | 1 | 0 | $5M | | | Neurology |
| urothelial cancer | 1 | 0 | $740M | 1 | 1 (0) | Oncology |
| uveal melanoma | 1 | 1 | $18M | | 1 (1) | Oncology |
| various autoimmune conditions | 1 | 0 | $242M | | | Rheumatology |
| vasomotor symptoms, postmenopausal | 1 | 1 | $32M | | | Women's health |
| venous thromboembolic event prevention | 1 | 0 | | | | Cardiovascular |
| venous thromboembolism in solid tumour | 1 | 0 | | | | Cardiovascular |
| venous thromboembolism prevention | 1 | 0 | $128M | 1 | | Cardiovascular |
| venous thromboembolism prevention and treatment | 1 | 0 | $32M | 1 | | Cardiovascular |
| venous thromboembolism prophylaxis | 1 | 0 | | | 2 (2) | Cardiovascular |
| vitreomacular traction syndrome | 1 | 0 | | | | Ophthalmology |
| wet age-related macular degeneration, central retinal vein occlusion, diabetic macular oedema | 1 | 0 | $506M | | | Ophthalmology |
| zygomycosis | 1 | 0 | $9M | | | Infectious disease |